Psychologists in Mendota Heights, MN Accepting Medicare
4 Psychologists found. Showing 1 - 4
 Mary Catherine Mckenna, M.A., L.P. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1316 Knollwood Ln, Mendota Heights, MN 55118 Phone: 651-552-6762 |
Dr. Amy Carrison, LP, LADC Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1155 Northland Dr, Mendota Heights, MN 55120 Phone: 612-223-9989 |
Chinyere Anuforo, MS Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1155 Northland Dr, Mendota Heights, MN 55120 Phone: 612-223-8899 |
Jaime Ascencio, LP Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1155 Northland Dr, Mendota Heights, MN 55120 Phone: 612-223-8898 |
News Archive
Twenty rising juniors to create bras during summer break
Students at the celebrated Otis College of Art and Design in Los Angeles will contribute decorated bras from the school's design competition for Chesapeake Regional Medical Center's 3rd annual October Bra-ha-ha.
Potential hazards of performing MRI in patients with cardiac pacemaker
Great care should be taken when performing magnetic resonance imaging (MRI) in patients with a cardiac pacemaker. Henning Bovenschulte and his co-authors review recent findings in the latest issue of Deutsches Ärzteblatt International.
Scientists discover possible way to stop activation of proteins known to cause age-related diseases
Researchers at the University of Surrey, in collaboration with the Universities of Reading and Cologne, and the Royal Berkshire Hospital, have discovered that it is possible to stop the activation of a group of proteins (NADPH Oxidase) known to cause most of the diseases of ageing.
Mylan announces FDA approval for Glipizide and Metformin Hydrochloride tablets
Mylan Laboratories has announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Glipizide and Metformin Hydrochloride Tablets in 2.5 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg strengths.
Injectable drug ocriplasmin improves vision in patients with symptomatic vitreomacular adhesion
In two ancillary studies of two multi-center international clinical trials led by the University of Southern California Eye Institute, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adhesion (VMA), a condition related to the aging eye that could cause permanent vision loss if left untreated.
› Verified 9 days ago
Counselors
Clinical Social Workers
Pharmacists
Dentists
Psychologists
Occupational Therapists